COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,436 Articles (22,835 medRxiv, 8,601 bioRxiv)

Most recent first Previous |  Page 1333: Articles 13321-13330  | Next

Did Low Risk Perception Mediate the COVID-19 Second Wave in Bangladesh? A Cross-sectional Study on Risk Perception and Preventive Practice
Rahman, F. N., Rahman, A. F., Hossain, S. M., Faiz, M. A., Faisel, A. J., Anwar, A. I., Hossain, M., Hussain, T. M., Mahbub, T., Ali, L.
10.1101/2021.08.08.21257737 — Posted: 2021-08-09
Occupational risk of SARS-CoV-2 infection and reinfection during the second pandemic surge: a cohort study.
Leidi, A., Berner, A., Roxane, D., Dubos, R., Koegler, F., Piumatti, G., Vuilleumier, N., Kaiser, L., Balavoine, J.-F., Trono, D., Pittet, D., Chappuis, F., Kherad, O., Courvoisier, D., Azman, A. S., Zaballa, M.-E., Guessous, I., Stringhini, S.
10.1101/2021.08.06.21261419 — Posted: 2021-08-08
Induction of cross-reactive antibody responses against the RBD domain of the spike protein of SARS-CoV-2 by commensal microbiota
Ninnemann, J., Budzinski, L., Bondareva, M., Witkowski, M., Angermair, S., Kreye, J., Durek, P., Reincke, M., Sanchez-Sendin, E., Yilmaz, S., Sempert, T., Heinz, G. A., Tizian, C., Raftery, M., Schoenrich, G., Matyushkina, D., Smirnov, I., Govorun, V., Schrezenmeier, E. V., Doerner, T., Zocche, S., Viviano, E., Sehmsdorf, K. J., Chang, H.-D., Enghard, P., Treskatsch, S., Radbruch, A., Diefenbach, A., Pruess, H., Mashreghi, M.-F., Kruglov, A.
10.1101/2021.08.08.455272 — Posted: 2021-08-08
Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses.
Wisnewski, A. V., Liu, J., Lucas, C. V., Klein, J., Iwasaki, A., Cantley, L., Fazen, L., Campillo Luna, J., Slade, M., Redlich, C.
10.1101/2021.08.05.21261616 — Posted: 2021-08-08
Awake Prone Position in Hypoxemic Patients with Coronavirus Disease 19 (COVI-PRONE): A Study protocol and Statistical Analysis Plan for Randomized Clinical Trial
Al Duhailib, Z., Arabi, Y., Culgin, S., Weatherald, J., Parhar, K. K. S., Nelson, K., Tamim, H., Alhazzani, W.
10.1101/2021.08.06.21261531 — Posted: 2021-08-08
Automated ELISA on-chip for the detection of an-ti-SARS-CoV-2 antibodies
Gonzalez-Gonzalez, E., Garcia-Ramirez, R., Diaz Armas, G. G., Esparza, M., Aguilar-Avelar, C., Flores-Contreras, E. A., Rodriguez-Sanchez, I. P., Delgado-Balderas, J. R., Soto-Garcia, B., Araiz-Hernandez, D., Abarca-Blanco, M., Yee-de Leon, J. R., Velarde-Calvillo, L. P., Abarca-Blanco, A., Yee-de Leon, J. F.
10.1101/2021.08.05.21261664 — Posted: 2021-08-08
Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blinded, Randomised, Placebo-Controlled Phase 2 Trial
Hsieh, S.-M., Liu, M.-C., Chen, Y.-H., Lee, W.-S., Hwang, S.-J., Cheng, S.-H., Ko, W.-C., Hwang, K.-P., Wang, N.-C., Lee, Y.-L., Lin, Y.-L., Shih, S.-R., Huang, C.-G., Liao, C.-C., Liang, J.-J., Chang, C.-S., Chen, C., Lien, C. E., Tai, I.-C., Lin, T.-Y.
10.1101/2021.08.05.21261532 — Posted: 2021-08-08 Discussion: Onsite
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Li, M., Yang, J., Wang, L., Wu, Q., Wu, Z., Zheng, W., Wang, L., Lu, W., Deng, X., Peng, C., Han, B., Zhao, Y., Yu, H., Yin, W.
10.1101/2021.08.03.21261544 — Posted: 2021-08-08
SARS-CoV-2 Suppression and Early Closure of Bars and Restaurants : A Longitudinal Natural Experiment
Takaku, R., Yokoyama, I., Tabuchi, T., Fujiwara, T.
10.1101/2021.08.07.21261741 — Posted: 2021-08-08
VPS29 exerts opposing effects on endocytic viral entry
Poston, D., Weisblum, Y., Hobbs, A., Bieniasz, P. D.
10.1101/2021.08.06.455441 — Posted: 2021-08-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).